The role of serum calprotectin as a novel biomarker in inflammatory bowel diseases: a review study

The role of serum calprotectin as a novel biomarker in inflammatory bowel diseases: a review study

As the incidence of inflammatory bowel diseases (IBD) increases in the newly industrialized countries, the health and financial burden of disease also increase. These changes make the role of IBD biomarkers further crucial. Serum calprotectin, as a novel blood-based biomarker of IBD, has been invest...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Gastroenterology and hepatology from bed to bench 2019-01, Vol.12 (3), p.183-189
Hauptverfasser: Azramezani Kopi, Tayebeh, Shahrokh, Shabnam, Mirzaei, Shahrokh, Asadzadeh Aghdaei, Hamid, Amini Kadijani, Azade
Format: Artikel
Sprache:eng
Schlagworte:
Review
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 189
container_issue 3
container_start_page 183
container_title Gastroenterology and hepatology from bed to bench
container_volume 12
creator Azramezani Kopi, Tayebeh
Shahrokh, Shabnam
Mirzaei, Shahrokh
Asadzadeh Aghdaei, Hamid
Amini Kadijani, Azade
description As the incidence of inflammatory bowel diseases (IBD) increases in the newly industrialized countries, the health and financial burden of disease also increase. These changes make the role of IBD biomarkers further crucial. Serum calprotectin, as a novel blood-based biomarker of IBD, has been investigated in several investigations. Yet, there is no consensus regarding its clinical utility. We searched the electronic database, including PubMed, EMBASE, Scopus, and Web of Science up to the end of 2018 to find how serum calprotectin associates with the disease characteristics in IBD. The search terms included: inflammatory bowel diseases, IBD, Crohn Diseases (CD), Ulcerative Colitis (UC), calprotectin, serum, and blood. Based on our review, a biomarker role has been suggested for serum calprotectin in IBD, as significant associations were found between serum calprotectin and disease burden, prognosis, and relapse. A complementary role to fecal calprotectin has also been suggested for serum calprotectin. On the other hand, considering a significant correlation between serum calprotectin and serum CRP, but not fecal calprotectin, serum calprotectin could be more representative of systemic inflammation than an intestinal inflammation. Consequently, further researches are needed to unwrap the potential of serum calprotectin as a blood-based biomarker in IBD.
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6668766</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2293021268</sourcerecordid><originalsourceid>FETCH-LOGICAL-p158t-34273a2b1b67306f1fb82bb128493280aac29df437936454c36981c657b61ff43</originalsourceid><addsrcrecordid>eNpVjs1qwzAQhE1paUKad9CxF4O0smW5h0IJ_QkEeknPQpLXjVrZciU7IW9fQ3PpXmaZYT7mKlsCpTIvgBfXlx-glItsndIXnY9zVlX1bbbgrATJKV1mZn9AEoNHElqSME4dsdoPMYxoR9cTnYgmfTiiJ8aFTsdvjGT2Xd963XV6DPFMTDjNeeMS6oTpYW5EPDo8kTROzfkuu2m1T7i-6Cr7eHneb97y3fvrdvO0ywdWyjHnBVRcg2FGVJyKlrVGgjEMZFFzkFRrC3XTFryquSjKwnJRS2ZFWRnB2tlfZY9_3GEyHTYW-zFqr4bo5tlnFbRT_5PeHdRnOCohhKyEmAH3F0AMPxOmUXUuWfRe9ximpABqToGBkPwX_hxtVg</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2293021268</pqid></control><display><type>article</type><title>The role of serum calprotectin as a novel biomarker in inflammatory bowel diseases: a review study</title><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Azramezani Kopi, Tayebeh ; Shahrokh, Shabnam ; Mirzaei, Shahrokh ; Asadzadeh Aghdaei, Hamid ; Amini Kadijani, Azade</creator><creatorcontrib>Azramezani Kopi, Tayebeh ; Shahrokh, Shabnam ; Mirzaei, Shahrokh ; Asadzadeh Aghdaei, Hamid ; Amini Kadijani, Azade</creatorcontrib><description>As the incidence of inflammatory bowel diseases (IBD) increases in the newly industrialized countries, the health and financial burden of disease also increase. These changes make the role of IBD biomarkers further crucial. Serum calprotectin, as a novel blood-based biomarker of IBD, has been investigated in several investigations. Yet, there is no consensus regarding its clinical utility. We searched the electronic database, including PubMed, EMBASE, Scopus, and Web of Science up to the end of 2018 to find how serum calprotectin associates with the disease characteristics in IBD. The search terms included: inflammatory bowel diseases, IBD, Crohn Diseases (CD), Ulcerative Colitis (UC), calprotectin, serum, and blood. Based on our review, a biomarker role has been suggested for serum calprotectin in IBD, as significant associations were found between serum calprotectin and disease burden, prognosis, and relapse. A complementary role to fecal calprotectin has also been suggested for serum calprotectin. On the other hand, considering a significant correlation between serum calprotectin and serum CRP, but not fecal calprotectin, serum calprotectin could be more representative of systemic inflammation than an intestinal inflammation. Consequently, further researches are needed to unwrap the potential of serum calprotectin as a blood-based biomarker in IBD.</description><identifier>ISSN: 2008-2258</identifier><identifier>EISSN: 2008-4234</identifier><identifier>PMID: 31528300</identifier><language>eng</language><publisher>Tehran, Iran: Shaheed Beheshti University of Medical Sciences</publisher><subject>Review</subject><ispartof>Gastroenterology and hepatology from bed to bench, 2019-01, Vol.12 (3), p.183-189</ispartof><rights>2019 RIGLD, Research Institute for Gastroenterology and Liver Diseases</rights><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6668766/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6668766/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,53791,53793</link.rule.ids></links><search><creatorcontrib>Azramezani Kopi, Tayebeh</creatorcontrib><creatorcontrib>Shahrokh, Shabnam</creatorcontrib><creatorcontrib>Mirzaei, Shahrokh</creatorcontrib><creatorcontrib>Asadzadeh Aghdaei, Hamid</creatorcontrib><creatorcontrib>Amini Kadijani, Azade</creatorcontrib><title>The role of serum calprotectin as a novel biomarker in inflammatory bowel diseases: a review study</title><title>Gastroenterology and hepatology from bed to bench</title><description>As the incidence of inflammatory bowel diseases (IBD) increases in the newly industrialized countries, the health and financial burden of disease also increase. These changes make the role of IBD biomarkers further crucial. Serum calprotectin, as a novel blood-based biomarker of IBD, has been investigated in several investigations. Yet, there is no consensus regarding its clinical utility. We searched the electronic database, including PubMed, EMBASE, Scopus, and Web of Science up to the end of 2018 to find how serum calprotectin associates with the disease characteristics in IBD. The search terms included: inflammatory bowel diseases, IBD, Crohn Diseases (CD), Ulcerative Colitis (UC), calprotectin, serum, and blood. Based on our review, a biomarker role has been suggested for serum calprotectin in IBD, as significant associations were found between serum calprotectin and disease burden, prognosis, and relapse. A complementary role to fecal calprotectin has also been suggested for serum calprotectin. On the other hand, considering a significant correlation between serum calprotectin and serum CRP, but not fecal calprotectin, serum calprotectin could be more representative of systemic inflammation than an intestinal inflammation. Consequently, further researches are needed to unwrap the potential of serum calprotectin as a blood-based biomarker in IBD.</description><subject>Review</subject><issn>2008-2258</issn><issn>2008-4234</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><recordid>eNpVjs1qwzAQhE1paUKad9CxF4O0smW5h0IJ_QkEeknPQpLXjVrZciU7IW9fQ3PpXmaZYT7mKlsCpTIvgBfXlx-glItsndIXnY9zVlX1bbbgrATJKV1mZn9AEoNHElqSME4dsdoPMYxoR9cTnYgmfTiiJ8aFTsdvjGT2Xd963XV6DPFMTDjNeeMS6oTpYW5EPDo8kTROzfkuu2m1T7i-6Cr7eHneb97y3fvrdvO0ywdWyjHnBVRcg2FGVJyKlrVGgjEMZFFzkFRrC3XTFryquSjKwnJRS2ZFWRnB2tlfZY9_3GEyHTYW-zFqr4bo5tlnFbRT_5PeHdRnOCohhKyEmAH3F0AMPxOmUXUuWfRe9ximpABqToGBkPwX_hxtVg</recordid><startdate>20190101</startdate><enddate>20190101</enddate><creator>Azramezani Kopi, Tayebeh</creator><creator>Shahrokh, Shabnam</creator><creator>Mirzaei, Shahrokh</creator><creator>Asadzadeh Aghdaei, Hamid</creator><creator>Amini Kadijani, Azade</creator><general>Shaheed Beheshti University of Medical Sciences</general><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20190101</creationdate><title>The role of serum calprotectin as a novel biomarker in inflammatory bowel diseases: a review study</title><author>Azramezani Kopi, Tayebeh ; Shahrokh, Shabnam ; Mirzaei, Shahrokh ; Asadzadeh Aghdaei, Hamid ; Amini Kadijani, Azade</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p158t-34273a2b1b67306f1fb82bb128493280aac29df437936454c36981c657b61ff43</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Review</topic><toplevel>online_resources</toplevel><creatorcontrib>Azramezani Kopi, Tayebeh</creatorcontrib><creatorcontrib>Shahrokh, Shabnam</creatorcontrib><creatorcontrib>Mirzaei, Shahrokh</creatorcontrib><creatorcontrib>Asadzadeh Aghdaei, Hamid</creatorcontrib><creatorcontrib>Amini Kadijani, Azade</creatorcontrib><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Gastroenterology and hepatology from bed to bench</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Azramezani Kopi, Tayebeh</au><au>Shahrokh, Shabnam</au><au>Mirzaei, Shahrokh</au><au>Asadzadeh Aghdaei, Hamid</au><au>Amini Kadijani, Azade</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The role of serum calprotectin as a novel biomarker in inflammatory bowel diseases: a review study</atitle><jtitle>Gastroenterology and hepatology from bed to bench</jtitle><date>2019-01-01</date><risdate>2019</risdate><volume>12</volume><issue>3</issue><spage>183</spage><epage>189</epage><pages>183-189</pages><issn>2008-2258</issn><eissn>2008-4234</eissn><abstract>As the incidence of inflammatory bowel diseases (IBD) increases in the newly industrialized countries, the health and financial burden of disease also increase. These changes make the role of IBD biomarkers further crucial. Serum calprotectin, as a novel blood-based biomarker of IBD, has been investigated in several investigations. Yet, there is no consensus regarding its clinical utility. We searched the electronic database, including PubMed, EMBASE, Scopus, and Web of Science up to the end of 2018 to find how serum calprotectin associates with the disease characteristics in IBD. The search terms included: inflammatory bowel diseases, IBD, Crohn Diseases (CD), Ulcerative Colitis (UC), calprotectin, serum, and blood. Based on our review, a biomarker role has been suggested for serum calprotectin in IBD, as significant associations were found between serum calprotectin and disease burden, prognosis, and relapse. A complementary role to fecal calprotectin has also been suggested for serum calprotectin. On the other hand, considering a significant correlation between serum calprotectin and serum CRP, but not fecal calprotectin, serum calprotectin could be more representative of systemic inflammation than an intestinal inflammation. Consequently, further researches are needed to unwrap the potential of serum calprotectin as a blood-based biomarker in IBD.</abstract><cop>Tehran, Iran</cop><pub>Shaheed Beheshti University of Medical Sciences</pub><pmid>31528300</pmid><tpages>7</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2008-2258
ispartof Gastroenterology and hepatology from bed to bench, 2019-01, Vol.12 (3), p.183-189
issn 2008-2258
2008-4234
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6668766
source EZB-FREE-00999 freely available EZB journals; PubMed Central
subjects Review
title The role of serum calprotectin as a novel biomarker in inflammatory bowel diseases: a review study
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-29T04%3A27%3A58IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20role%20of%20serum%20calprotectin%20as%20a%20novel%20biomarker%20in%20inflammatory%20bowel%20diseases:%20a%20review%20study&rft.jtitle=Gastroenterology%20and%20hepatology%20from%20bed%20to%20bench&rft.au=Azramezani%20Kopi,%20Tayebeh&rft.date=2019-01-01&rft.volume=12&rft.issue=3&rft.spage=183&rft.epage=189&rft.pages=183-189&rft.issn=2008-2258&rft.eissn=2008-4234&rft_id=info:doi/&rft_dat=%3Cproquest_pubme%3E2293021268%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2293021268&rft_id=info:pmid/31528300&rfr_iscdi=true